First record of Bulimulus tenuissimus (Mollusca) as potential experimental intermediate host of Angiostrongylus cantonensis (Nematoda)

Authors: Martins, F. G., Garcia, J. S., Torres, E. J. L., Santos, M. A. J., Massard, C. L., Pinheiro, J.

Source: Brazilian Journal of Biology. November 2019 79(4)

Subject Terms: Bulimulus tenuissimus, Bulimulidae, Metastrogylidae, potential new intermediate host

File Description: text/html

Access URL: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-69842019000400686

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study

Authors: Charton, E., Baldini, C., Fayet, Y., Schultz, E., Auroy, L., Vallier, E., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Touzeau, C., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.-J., Delord, J.-P., Gomez Roca, C., Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.-C., Massard, C., Besle, S.

Source: In ESMO Open August 2023 8(4)

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

Authors: Simonelli, M., Garralda, E., Eskens, F., Gil-Martin, M., Yen, C.-J., Obermannova, R., Chao, Y., Lonardi, S., Melichar, B., Moreno, V., Yu, M.-L., Bongiovanni, A., Calvo, E., Rottey, S., Machiels, J.-P., Gonzalez-Martin, A., Paz-Ares, L., Chang, C.-L., Mason, W., Lin, C.-C., Reardon, D.A., Vieito, M., Santoro, A., Meng, R., Abbadessa, G., Menas, F., Lee, H., Liu, Q., Combeau, C., Ternes, N., Ziti-Ljajic, S., Massard, C.

Source: In ESMO Open October 2022 7(5)

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study

Authors: Baldini, C., Charton, E., Schultz, E., Auroy, L., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Le Gouill, S., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.J., Delord, J.P., Roca, C. Gomez, Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.C., Massard, C., Besle, S.

Source: In ESMO Open June 2022 7(3)

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

Authors: Nassif, E.F., Blay, J.-Y., Massard, C., Dufresne, A., Brahmi, M., Cassier, P., Ray-Coquard, I., Pautier, P., Leary, A., Sunyach, M.-P., Bahleda, R., Levy, A., Le Pechoux, C., Honoré, C., Mir, O., Le Cesne, A.

Source: In ESMO Open April 2022 7(2)

Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance

Authors: Loriot, Y., Marabelle, A., Guégan, J.P., Danlos, F.X., Besse, B., Chaput, N., Massard, C., Planchard, D., Robert, C., Even, C., Khettab, M., Tselikas, L., Friboulet, L., André, F., Nafia, I., Le Loarer, F., Soria, J.C., Bessede, A., Italiano, A.

Source: In Annals of Oncology November 2021 32(11):1381-1390

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

Authors: Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein Jr G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC

Source: Cancer Management and Research, Vol Volume 11, Pp 10463-10476 (2019)

Subject Terms: cc-115, mtorc1/mtorc2, mtor inhibitor, dna-pk inhibitor, phase i study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/first-in-human-phase-i-study-of-a-dual-mtor-kinase-and-dna-pk-inhibito-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322

Access URL: https://doaj.org/article/4b4587face0b41eb9b636b544af18519

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

Authors: Bernard-Tessier, A., Baldini, C., Martin, Patricia, Champiat, Stéphane, Hollebecque, Antoine, Postel-Vinay, Sophie, Varga, Andrea, Bahleda, Rastilav, Gazzah, Anas, Michot, Jean-Marie, Ribrag, Vincent, Armand, Jean-Pierre, Marabelle, Aurélien, Soria, Jean-Charles, Massard, C.

Source: In European Journal of Cancer September 2018 101:160-164

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Authors: Massard, C. ^*, Azaro, A., Soria, J.-C., Lassen, U., Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B.K.R., Yuen, E.S.M., Benhadji, K.A., Rodon, J.

Source: In Annals of Oncology September 2018 29(9):1911-1917

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Authors: Hansen, A.R. ^*, Massard, C., Ott, P.A., Haas, N.B., Lopez, J.S., Ejadi, S., Wallmark, J.M., Keam, B., Delord, J.-P., Aggarwal, R., Gould, M., Yang, P., Keefe, S.M., Piha-Paul, S.A.

Source: In Annals of Oncology August 2018 29(8):1807-1813

Apport et méthodologies innovantes des essais de phase I en oncologie thoracique : des phases 1 aux essais BASKET/plateforme

Authors: Massard, C. ^*

Source: In Revue des Maladies Respiratoires Actualités October 2022 14(2) Supplement 1

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours

Authors: Herin, H., Aspeslagh, S., Castanon, E., Dyevre, V., Marabelle, A., Varga, A., Postel Vinay, S., Michot, J.M., Ribrag, V., Gazzah, A., Bahleda, R., Mir, O., Massard, C., Hollebecque, A., Soria, J.C., Baldini, C.

Source: In European Journal of Cancer May 2018 95:68-74

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours

Authors: Hollebecque, A., Bahleda, R., Faivre, L., Adam, J., Poinsignon, V., Paci, A., Gomez-Roca, C., Thery, J.C., Le Deley, M.C., Varga, A., Gazzah, A., Ileana, E., Gharib, M., Angevin, E., Malekzadeh, K., Massard, C., Soria, J.C., Spano, J.P.

Source: In European Journal of Cancer August 2017 81:81-89

Surveillance et adaptation de la stratégie thérapeutique en cas de progression de la maladie dans le cancer de la prostate avancé : résultats d’une enquête nationale

Alternate Title: Management of a progressing prostate cancer: results of a national study (English)

Authors: Rozet, F., Roupret, M., Hennequin, C., Massard, C., Blanchard, P., Le Moulec, S.

Source: In Progres en Urologie May 2017 27(6):381-388

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

Authors: Massard, C. ^*, Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C.J., Petrylak, D.P., Attard, G., Shen, L., Fizazi, K., de Bono, J.

Source: In Annals of Oncology January 2017 28(1):90-95

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Authors: Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., Massard, C., Fuerea, A., Ribrag, V., Gazzah, A., Armand, J.P., Amellal, N., Angevin, E., Noel, N., Boutros, C., Mateus, C., Robert, C., Soria, J.C., Marabelle, A., Lambotte, O.

Source: In European Journal of Cancer February 2016 54:139-148

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Authors: Postel-Vinay, S. ^*, Boursin, Y., Massard, C., Hollebecque, A., Ileana, E., Chiron, M., Jung, J., Lee, J.S., Balogh, Z., Adam, J., Vielh, P., Angevin, E., Lacroix, L., Soria, J.-C.

Source: In Annals of Oncology February 2016 27(2):344-352

6O Subcutaneous fat mass predicts progression-free survival in patients treated with antibody drug conjugates in early phase clinical trials

Authors: Delaye, M., Lawrance, L., Belkouchi, Y., Decazes, P., Wirth, F., Bône, A., Ouali, K., Hollebecque, A., Smolenschi, C., Champiat, S., Danlos, F-X., Beshiri, K., Sakkal, M., Massard, C., Vera, P., Marabelle, A., Aix, S. Ponce, Lassau, N., Ammari, S., Baldini, C.

Source: In ESMO Open February 2024 9 Supplement 1

Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project

Authors: Kramar, Andrew, Sylvester, Richard, Filleron, Thomas, Negrier, Sylvie, Joniau, Steven, Mulders, Peter, Powles, Thomas, Escudier, Bernard, Bex, Axel, Bonnetain, Franck, Bossi, Alberto, Braccarda, Sergio, Bukowski, Ronald, Catto, James, Choueiri, Toni, Crabb, Simon, Eisen, Tim, El Demery, Mounira, Fitzpatrick, John, Flamand, Vincent, Goebell, Peter J., Gravis, Gwendael, Houédé, Nadine, Jacqmin, Didier, Kaplan, Richard, Malavaud, Bernard, Massard, Christophe, Melichar, Bohuslav, Mourey, Loïc, Nathan, Paul, Pasquier, David, Porta, Camillo, Pouessel, Damien, Quinn, David, Ravaud, Alain, Rolland, Frédéric, Schmidinger, Manuela, Tombal, Bertrand, Tosi, Diego, Vauleon, Elodie, Volpe, Alessandro, Wolter, Pascal, Kramar, A., Negrier, S., Sylvester, R., Joniau, S., Mulders, P., Powles, T., Bex, A., Bonnetain, F., Bossi, A., Bracarda, S., Bukowski, R., Catto, J., Choueiri, T.K., Crabb, S., Eisen, T., El Demery, M., Fitzpatrick, J., Flamand, V., Goebell, P.J., Gravis, G., Houédé, N., Jacqmin, D., Kaplan, R., Malavaud, B., Massard, C., Melichar, B., Mourey, L., Nathan, P., Pasquier, D., Porta, C., Pouessel, D., Quinn, D., Ravaud, A., Rolland, F., Schmidinger, M., Tombal, B., Tosi, D., Vauleon, E., Volpe, A., Wolter, P., Escudier, B., Filleron, T. ^*

Source: In Annals of Oncology December 2015 26(12):2392-2398

Évaluation de la réponse métabolique en TEP/TDM à la F18-FCH après un mois de traitement par acétate d’abiratérone chez les patients présentant un cancer de la prostate métastatique résistant à la castration

Alternate Title: Early response assessment in 18F-choline PET/CT for patients with castrate-resistant metastatic prostate cancer after one-month treatment with acetate abiraterone (English)

Authors: Boughdad, S., Le Moulec, S., Massard, C., Farace, F., Vielh, P., Aupée, O., Métivier, D., Védrine, L., Gontier, E.

Source: In Medecine Nucleaire September 2015 39(4):386-395